Last reviewed · How we verify
CancerVax vaccine (CANVAXIN)
CancerVax vaccine (CANVAXIN) is a Therapeutic cancer vaccine Biologic drug developed by CancerVax Corporation. It is currently in Phase 3 development for Melanoma (adjuvant setting), Metastatic melanoma.
CANVAXIN is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
CANVAXIN is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Melanoma (adjuvant setting), Metastatic melanoma.
At a glance
| Generic name | CancerVax vaccine (CANVAXIN) |
|---|---|
| Sponsor | CancerVax Corporation |
| Drug class | Therapeutic cancer vaccine |
| Target | MAGE-1, MAGE-3 (melanoma-associated antigens) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CANVAXIN is an autologous whole-cell vaccine derived from two human melanoma cell lines that express common tumor-associated antigens (MAGE-1 and MAGE-3). It is designed to activate T-cell mediated immunity against melanoma cells expressing these antigens, enabling the patient's immune system to target and eliminate cancer cells. The vaccine approach aims to provide durable anti-tumor immunity by priming cytotoxic T lymphocytes.
Approved indications
- Melanoma (adjuvant setting)
- Metastatic melanoma
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Chills
Key clinical trials
- Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (PHASE3)
- Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma (PHASE2)
- Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma (PHASE2)
- Vaccine Therapy in Treating Patients With Malignant Melanoma (PHASE2)
- Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma (PHASE2)
- Vaccine Therapy for Patients With Stage III Melanoma (PHASE3)
- Vaccine Therapy for Patients With Stage IV Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CancerVax vaccine (CANVAXIN) CI brief — competitive landscape report
- CancerVax vaccine (CANVAXIN) updates RSS · CI watch RSS
- CancerVax Corporation portfolio CI
Frequently asked questions about CancerVax vaccine (CANVAXIN)
What is CancerVax vaccine (CANVAXIN)?
How does CancerVax vaccine (CANVAXIN) work?
What is CancerVax vaccine (CANVAXIN) used for?
Who makes CancerVax vaccine (CANVAXIN)?
What drug class is CancerVax vaccine (CANVAXIN) in?
What development phase is CancerVax vaccine (CANVAXIN) in?
What are the side effects of CancerVax vaccine (CANVAXIN)?
What does CancerVax vaccine (CANVAXIN) target?
Related
- Drug class: All Therapeutic cancer vaccine drugs
- Target: All drugs targeting MAGE-1, MAGE-3 (melanoma-associated antigens)
- Manufacturer: CancerVax Corporation — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Melanoma (adjuvant setting)
- Indication: Drugs for Metastatic melanoma
- Compare: CancerVax vaccine (CANVAXIN) vs similar drugs
- Pricing: CancerVax vaccine (CANVAXIN) cost, discount & access